Our funding partners
The Institute of Cancer Research works closely with a number of funding and research organisations, including Cancer Research UK, Breast Cancer Now and Wellcome.
We also have a close partnership with The Royal Marsden NHS Foundation Trust, allowing effective translation of scientific results into new treatments for patients.
Cancer Research UK
A range of the work at the ICR is supported by Cancer Research UK – the UK’s largest cancer research charity. Where Cancer Research UK is the main external funder, the CRUK commercial partnership team will work with the ICR in determining the best route for commercial exploitation and identifying suitable collaborators; CRUK may lead on negotiations. The Enterprise Unit works closely with CRT to ensure that the exploitation strategy matches the ICR’s mission.
The Royal Marsden NHS Foundation Trust
The ICR works closely with our clinical partner, The Royal Marsden NHS Foundation Trust – a world-leading cancer centre specialising in cancer diagnosis, treatment, research and education. Together, we form the largest comprehensive cancer centre in Europe. Through this partnership, we undertake ground-breaking research into new cancer drug therapies and treatments.
Any IP generated through joint ICR-Royal Marsden projects is managed by the Enterprise Unit and any benefits shared.
The Wellcome Trust
The Wellcome Trust is a charitable research foundation dedicated to achieving improvements in human health. The Wellcome Trust funds a number of major research programmes at the ICR including three Seeding Drug Discovery Initiative Awards. IP generated from Wellcome Trust projects is owned by the ICR.
Commercial interactions may be led by either the Enterprise Unit or the Wellcome Trust but the Enterprise Unit plays an active role in all projects, from the preparation of applications to the subsequent exploitation of the results.
Breast Cancer Now
The Breast Cancer Research Centre at the ICR is supported by Breast Cancer Now and brings together 140 doctors and scientists to carry out research into the causes and treatment of breast cancer. Any IP generated through joint ICR-Breast Cancer Now projects will be owned jointly by ICR and Breast Cancer Now. It is managed by the Enterprise Unit and any benefits shared.Related news
945x532.png?sfvrsn=310c2acf_2 "Cell Division-(green-4-3)945x532")
Related blogs
Despite significant advancements in cancer treatment, immunotherapy has shown limited success in treating prostate cancer due to the unique resistance mechanisms of its tumours. However, researchers at The Institute of Cancer Research, London, are optimistic about a new form of targeted immunotherapy that hopes to overcome these challenges.